Evidence map›Paper›PMID 42164623›Full record

ArticleUrology case reports2026

Metastatic Leydig cell tumor: A case report and review of the literature.

Faisl Alslimah, Mohammed Radwan, Mutasim Alkhalifah, Fawaz Alkeraithe, Ali Alzughbi, Mofarej Alhogbani, Naif Aldhaam

Abstract readCase Reports
In one paragraph

Article in Urology case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Faisl AlslimahDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.
Mohammed RadwanDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.
Mutasim AlkhalifahDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.
Fawaz AlkeraitheDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.
Ali AlzughbiDepartment of Pathology, King Fahad Medical City, Riyadh, Saudi Arabia.
Mofarej AlhogbaniDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.
Naif AldhaamDepartment of Urology, King Fahad Medical City, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leydig cell tumors are rare sex cord-stromal neoplasms, mostly benign, with about 10% malignant. A 42-year-old man presented with a 6 cm right testicular mass and sclerotic bone lesions, normal tumor markers, and no lymphadenopathy. Orchidectomy showed a Leydig cell tumor with vascular invasion but no marked atypia. Follow-up was irregular. After 24 months, imaging revealed an 8 × 7.5 cm retroperitoneal mass; biopsy confirmed metastasis. RPLND removed a single involved lymph node. Testosterone fell from >120 nmol/L to 2.30 nmol/L postoperatively. Despite limited risk factors, metastatic disease occurred, highlighting unpredictability, chemoresistance, and importance of surveillance and aggressive surgical management.

Identifiers

PMID42164623
PMCPMC13185764

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.